Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review

References

• Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Curr Opin Pediatr. 2020;32(1):57–66. doi:10.1097/MOP.0000000000000855
   PubMed Web of Science ®Google Scholar
• Conneely SE, Stevens AM. Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy. Curr Oncol Rep. 2021;23:16. doi:10.1007/s11912-020-01009-3
   PubMed Web of Science ®Google Scholar
• Wang J, Ouyang J, Zhou R, Chen B, Yang Y. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol. 2010;124:61–71. doi:10.1159/000314273
   PubMed Web of Science ®Google Scholar
• Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst. 2004;96:38–45. doi:10.1093/jnci/djh003
   PubMed Web of Science ®Google Scholar
• Levi I, Grotto I, Yerushalmi R, Ben-Bassat I, Shpilberg O. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res. 2004;28:605–612. doi:10.1016/j.leukres.2003.10.029
   PubMed Web of Science ®Google Scholar
• Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant. 2002;29:843–852. doi:10.1038/sj.bmt.1703528
   PubMed Web of Science ®Google Scholar
• Amadori S, Testi AM, Aricò M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol. 1995;11(6):1046–1054. doi:10.1200/JCO.1993.11.6.1046
   Web of Science ®Google Scholar
• Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from Children’s Cancer Group. Blood. 2001;97(1):56–62. doi:10.1182/blood.v97.1.56
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996;334:1428–1434. doi:10.1056/NEJM199605303342203
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Bergin ME, Burgess MA, et al. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation. J Clin Oncol. 1994;12(10):2138–2145. doi:10.1200/JCO.1994.12.10.2138
   PubMed Web of Science ®Google Scholar
• Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council’s 10th AML trial. Br J Haematol. 1998;101:130–140. doi:10.1046/j.1365-2141.1998.00677.x
   PubMed Web of Science ®Google Scholar
• Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–3205. doi:10.1182/blood-2012-03-362608
   PubMed Web of Science ®Google Scholar
• Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170–178. doi:10.1182/blood-2013-03-491621
   PubMed Web of Science ®Google Scholar
• Sakaguchi H, Muramatsu H, Hasegawa D, et al. Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: a nationwide retrospective study in Japan. Pediatr Blood Cancer. 2019;66:e27459. doi:10.1002/pbc.27459
   PubMed Web of Science ®Google Scholar
• Alonzo TA, Wells RJ, Woods WG, et al. Postremission therapy for children with acute myeloid leukemia: the Children’s Cancer Group experience in the transplant era. Leukemia. 2005;19:965–970. doi:10.1038/sj.leu.2403763
   PubMed Web of Science ®Google Scholar
• Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217–223. doi:10.1056/NEJM199501263320403
   PubMed Web of Science ®Google Scholar
• Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19:2043–2053. doi:10.1038/sj.leu.2403869
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2007;13:1–25. doi:10.1016/j.bbmt.2006.10.024
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendation from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113(9):1875–1891. doi:10.1182/blood-2008-04-150250
   PubMed Web of Science ®Google Scholar
• Sanz J, Montesinos P, Sanz AM. Role of hematopoietic stem cell transplant in acute promyelocytic leukemia. Front Oncol. 2021;11:614215e.
   PubMed Web of Science ®Google Scholar
• Sanz J, Labopin M, Sanz MA, et al. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplant. 2021;56(6):1272–1280. doi:10.1038/s41409-020-01162-0
   PubMed Web of Science ®Google Scholar
• Chakrabarty JLH, Rubinger M, Le Rademacher J, et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant. 2014;20(7):1021.1025. doi:10.1016/j.bbmt.2014.03.025
   Web of Science ®Google Scholar
• Abla O, Kutney MA, Testi AM, et al. Management of relapsed and refractory childhood acute promyelocytic leukemia: recommendation from an international expert panel. Br J Haematol. 2016;175:588–601. doi:10.1111/bjh.14313
   PubMed Web of Science ®Google Scholar
• Termulhen AM, Klopfenstein K, Olshefski R, et al. Mobilization of PML-RARA negative blood stem cell transplantation in children with relapsed acute promyelocytic leukemia. Pediatr Blood Cancer. 2008;51:521–524. doi:10.1002/pbc.21514
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Agaewal MA, Dahl GV, Gregory JJ, Feusner JH. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant. 2008;14:824–830. doi:10.1016/j.bbmt.2008.04.015
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tomizawa D, Kudo K, et al. Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatr Blood Cancer. 2020;67(5):e28181. doi:10.1002/pbc.28181
   PubMed Web of Science ®Google Scholar
• Testi AM, Mohamed S, Diverio D, et al. Outcome of relapsed/refractory acute promyelocytic leukemia in children, adolescents and young adult patients – a 25-year Italian experience. Br J Haematol. 2021;195(2):278–283. doi:10.1111/bjh.17637
   PubMed Web of Science ®Google Scholar
• Scheinemann K, Weitzman S, Hitzler J, Doyle J, Abla O. Isolated central nervous system relapse in childhood acute promyelocytic leukemia. J Pediatr Hematol Oncol. 2008;30(2):160–162. doi:10.1097/MPH.0b013c318159a582
   PubMed Web of Science ®Google Scholar
• Billet AL, Kornmehl E, Tabell NJ, et al. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993;81(6):1651–1657.
   PubMed Web of Science ®Google Scholar
• Billet AL, Sallan SE. Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging. Am J Pediatr Hematol Oncol. 1993;15(2):162–168.
   PubMedGoogle Scholar
• Maldonado MS, Diaz-Heredia C, Badell J, et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplant. 1998;22:1043–1047. doi:10.1038/sj.bmt.1701507
   PubMed Web of Science ®Google Scholar
• Messina C, Cesaro S, Rondelli R, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in Italy. Bone Marrow Transplant. 1998;21:1015–1021.
   PubMed Web of Science ®Google Scholar
• Borgmann A, Schmid H, Hartmann R, et al. Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. Lancet. 1995;346:873–876. doi:10.1016/s0140-6736(95)92710-7
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Gaipa G, Bonanomi S, et al. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. Leukemia. 2001;15:50–56. doi:10.1038/sj.leu.2402004
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Galimberti S, Valsecchi MG, et al. Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse. Pediatr Blood Cancer. 2011;57:654–659. doi:10.1002/pbc.23169
   PubMed Web of Science ®Google Scholar
• Houtenbos I, Bracho F, Davenport V, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immune- and chemotherapy (PTIC). Bone Marrow Transplant. 2001;27:145–153. doi:10.1038/sj.bmt.1702750
   PubMed Web of Science ®Google Scholar
• Ribera JM, Ortega JJ, Oriol A, et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol. 2007;25(1):16–24. doi:10.1200/JCO.2006.06.8312
   PubMed Web of Science ®Google Scholar
• Hong CR, Kang HJ, Park KD, Shin HY, Ahn HS. High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia. J Hematol. 2018;107:355–362. doi:10.1007/s12185-017-2355-5
   Google Scholar
• Capria V, Pepe S, Trisolini SM, et al. Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease. Leuk Lymphoma. 2019;60(1):274–276. doi:10.1080/10428194.2018.1468895
   PubMed Web of Science ®Google Scholar
• Smith SM, Hijiya N, Sakamoto KM. Chronic Myelogenous Leukemia in childhood. Curr Oncol Rep. 2021;23:40. doi:10.1007/s11912-021-01025-x
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review. 1975–2017. National Cancer Institute Bethesda, MD, based on November 2019 SEER data submission, posted to the SEER web site, April 2020. Available from: https://seercancergrov/197529017/. Accessed May 15 2023.
   Google Scholar
• Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374–2384. doi:10.1182/blood.2018882233
   PubMed Web of Science ®Google Scholar
• Athale U, Hijiya N, Patterson BC, et al. Management of chronic myeloid leukemia (CML) in children and adolescents: recommendations from the Children’s Oncology Group CML Working Group. Pediatr Blood Cancer. 2019;66(9):e27827. doi:10.1002/pbc.27827
   PubMed Web of Science ®Google Scholar
• Bower H, Biorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857. doi:10.1200/JCO.2015.66.2866
   PubMed Web of Science ®Google Scholar
• Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukemia in tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):c186–c193. doi:10.1016/S2352-3026(15)00048-4
   PubMed Web of Science ®Google Scholar
• Gore L, Kearns PR, de Martino ML, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a Phase II trial. J Clin Oncol. 2018;36(13):1330–1338. doi:10.1200/JCO.2017.75.9597
   PubMed Web of Science ®Google Scholar
• Hijiya N, Maschan A, Rizzari C, et al. Efficacy and safety of nilotinib in pediatric patients with Philadelphia chromosome-positive (PH+) chronic myeloid leukemia (CML): results from a Phase 2 trial (abstract). Pediatr Blood Cancer. 2017;64(S3):Abstract S22.
   Google Scholar
• Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at pre-pubertal and pubertal age of children with chronic myeloid leukemia. J Pediatr. 2011;159(4):676–681. doi:10.1016/j.jpeds.2011.03.046
   PubMed Web of Science ®Google Scholar
• Bansal D, Shava U, Verma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59(3):481–484. doi:10.1002/pbc.23389
   PubMed Web of Science ®Google Scholar
• Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endo-crinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63(8):1332–1338. doi:10.1002/pbc.26028
   PubMed Web of Science ®Google Scholar
• Shima H, Kada A, Tanizawa A, et al. Discontinuation of tyrosine kinase inhibitor in children with chronic myeloid leukemia (JPLSG STKI-14 Study). Blood. 2019;134(Supplement1):25. doi:10.1182/blood.2019-122623
   Google Scholar
• Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase: imatinib cessation in children with CML. Pediatr Blood Cancer. 2014;61(2):355–357. doi:10.1002/pbc.24521
   PubMed Web of Science ®Google Scholar
• Giona F, Malaspina F, Putti MC, et al. Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukemia. Br J Haematol. 2020;188(6):e101–e105. doi:10.1111/bjh.16388
   PubMed Web of Science ®Google Scholar
• Meloni G, De Fabritiis P, Alimena G, et al. Autologous bone marrow transplantation or peripheral blood stem cell transplantation for patients with chronic myelogenous leukemia in chronic phase. Bone Marrow Transplant. 1880;4:92–94.
   Google Scholar
• Hoyle C, Gray R, Gpòdman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol. 1994;86:76–81. doi:10.1111/j.1365-2141.1994.tb03255.x
   PubMed Web of Science ®Google Scholar
• Pigneux A, Faberes C, Boiron JM, et al. Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. Bone Marrow Transplant. 1999;24:265–270. doi:10.1038/sj.bmt.1701871
   PubMedGoogle Scholar
• Olavarria E, Reiffers J, Boque C, et al. The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukemia in chronic phase. Br J Haematol. 2002;118:762–770. doi:10.1046/j.1365-2141.2002.03600.x
   PubMed Web of Science ®Google Scholar
• Olavarria E. Autologous stem cell transplantation in chronic myeloid leukemia. Semin Hematol. 2007;44(4):252–258. doi:10.1053/j.seminhematol.2007.08.003
   PubMed Web of Science ®Google Scholar
• Bhatia R, McGlave PB. Autologous hematopoietic cell transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:715–732. doi:10.1016/j.hoc.2004.03.006
   PubMed Web of Science ®Google Scholar
• Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A; United Kingdom Chronic Myeloid Leukemia (UK CML) Working Party. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol. 2003;123:479–483. doi:10.1046/j.1365-2141.2003.04599.x
   PubMed Web of Science ®Google Scholar
• Kreuzer KA, Kluhs C, Baskaynak G, Novassaghi K, Dorken B, le Coutre P. Filgrastim-induced stem cell mobilization in chronic myeloid leukemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol. 2004;124:195–199. doi:10.1046/j.1365-2141.2003.04756.x
   PubMed Web of Science ®Google Scholar
• Perseghin P, Gambacorti-Passerini C, Tornaghi C, et al. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion. 2005;45:1214–1229. doi:10.1111/j.1537-2995.2005.00175.x
   PubMed Web of Science ®Google Scholar
• Cairo MS, Beishuizen A. Childhood, adolescents and young adults with non-Hodgkin lymphoma: current perspectives. Br J Haematol. 2019;185(6):1021–1042. doi:10.1111/bjh.15764
   PubMed Web of Science ®Google Scholar
• Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. Br J Hematol. 2019;185:1071–1085. doi:10.1111/bjh.15734
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Taj M, Garnier N, et al. Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers. 2021;13(9):2075. doi:10.3390/cancers13092075
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group Report. Leukemia. 2013;27:1174–1177. doi:10.1038/leu.2012.255
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology report. Br J Haematol. 2014;167:394–401. doi:10.1111/bjh.13040
   PubMed Web of Science ®Google Scholar
• Loiseau HA, Hartmann O, Valteau D, et al. High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1991;8(6):465–472.
   PubMed Web of Science ®Google Scholar
• Bureo E, Ortega JJ, Munoz A, et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin lymphoma. Spanish Working Party for Bone Marrow transplantation in children. Bone Marrow Transplant. 1995;15:353–359.
   PubMed Web of Science ®Google Scholar
• Won SC, Han JW, Known SY, et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin’s lymphoma: a report from Korean society of pediatric hematology-oncology. Ann Hematol. 2006;85:787–794. doi:10.1007/s00277-006-0169-2
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L, Ricafort L, Keman NA, et al. Ten-year follow up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer. 2013;60(12):2018–2024. doi:10.1002/pbc.24722
   PubMed Web of Science ®Google Scholar
• Philip T, Bergeron C, Frappaz D. Management of paediatric lymphoma. Baillieres Clin Haematol. 1996;9(4):769–797. doi:10.1016/s0950-3536(96)80053-9
   PubMedGoogle Scholar
• Harris RE, Termuhlen AM, Smith ML, et al. Autologous peripheral blood stem cell transplantation in children with relapsed or refractory lymphoma: results of Children’s Oncology Group Study A5962. Biol Blood Marrow Transplant. 2011;17(2):249–258. doi:10.1016/j.bbmt.2010.07.002
   PubMed Web of Science ®Google Scholar
• Jourdan A, Auperin A, Minard-Colin V, et al. Outcome and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societè Francaise des Cancers de l’Enfant Study. Haematologica. 2015;100(6):810–817. doi:10.3324/haematol.2014.121434
   PubMed Web of Science ®Google Scholar
• Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study. Pediatr Blood Cancer. 2019;66(9):e27873. doi:10.1002/pbc.27873
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Meinhardt A, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135(14):1124–1132. doi:10.1182/blood.2019003591
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt’s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation registry. Blood. 1997;90:2921–2930.
   PubMed Web of Science ®Google Scholar
• Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16:223–230. doi:10.1016/j.bbmt.2009.09.021
   PubMed Web of Science ®Google Scholar
• Hazar V, Kesik V, Karasu GT, et al. Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry. Leuk Lymphoma. 2018;59(1):85–96. doi:10.1080/10428194.2017.1330472
   PubMed Web of Science ®Google Scholar
• Satwani P, Jin Z, Martin PL, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29:448–455. doi:10.1038/leu.2014.194
   PubMed Web of Science ®Google Scholar
• Gardenswartz A, Mehta B, El-Mallawany N, et al. Safety and efficacy of myeloablative conditioning autologous stem cell transplantation, target immunotherapy, and reduced intensity conditioning allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non Hodgkin lymphoma. Br J Haematol. 2018;182(Suppl. 1):23 (abstract 28).
   Google Scholar
• Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusion of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102:2086–2096. doi:10.3324/haematol.2015.139162
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Hemiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019;185(6):1158–1170. doi:10.1111/bjh.15793
   PubMed Web of Science ®Google Scholar
• Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescents. Pediatr Hematol Oncol. 2013;30:484–508. doi:10.3109/08880018.2013.789574
   PubMed Web of Science ®Google Scholar
• Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M. Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009;52:591–595. doi:10.1002/pbc.21941
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Reiter A, Landmann E, et al. Poor outcome of children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from Berlin-Frankfurt- Muenster Group. J Clin Oncol. 2009;27:3363–3369. doi:10.1200/JCO.2008.19.3367
   PubMed Web of Science ®Google Scholar
• Michaux K, Bergeron C, Gandemer V, Mechinaud F, Uyttebroeck A, Bertrand Y; SFCE: the EORTC Children Leukemia Group. Relapsed or refractory lymphoblastic lymphoma in children: results and analysis of 23 patients in the EOTC 58951 and the LMT96 protocols. Pediatr Blood Cancer. 2016;63:1214–1221. doi:10.1002/pbc.25990
   PubMed Web of Science ®Google Scholar
• Brugieres L, Deley MC, Pacquement H, et al. CD30 (+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591–3598.
   PubMed Web of Science ®Google Scholar
• Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM 90. Blood. 2001;97:3699–3706. doi:10.1182/blood.v97.12.3699
   PubMed Web of Science ®Google Scholar
• Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: a report from the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104:2133–2140. doi:10.1002/cncr.21438
   PubMed Web of Science ®Google Scholar
• Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52:335–339. doi:10.1002/pbc.21817
   PubMed Web of Science ®Google Scholar
• Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children – a report from French Society of Pediatric Oncology. Ann Oncol. 2000;11:53–58. :
   PubMed Web of Science ®Google Scholar
• Mori T, Takimoto T, Katano N, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2006;132:594–597. doi:10.1111/j.1365-2141.2005.05910.x
   PubMed Web of Science ®Google Scholar
• Fukano R, Mori T, Kobayashi R, et al. Hematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. Br J Haematol. 2015;168(4):557–563. doi:10.1111/bjh.13167
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065–3071. doi:10.1200/JCO.2011.34.8417
   PubMed Web of Science ®Google Scholar
• Knorr F, Brugieres L, Pillon M, et al. European Intergroup for Childhood Non-Hodgkin Lymphoma. Stem cell transplant and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the International, prospective ALCL-relapse trial. J Clin Oncol. 2020;38(34):3999–4009. doi:10.1200/JCO.20.00157
   PubMed Web of Science ®Google Scholar
• Attarbaschi A, Abla O, Padilla LA, et al. Rare non-Hodgkin lymphoma of childhood and adolescents: a consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma and nonanaplastic peripheral T-cell lymphoma. Pediatr Blood Cancer. 2020;67(8):e28416. doi:10.1002/pbc.28416
   PubMed Web of Science ®Google Scholar
• Mellgren K, Attarbashi A, Abla O, et al. Non-anaplastic peripheral T cell lymphoma in children and adolescents – an international review of 143 cases. Ann Hematol. 2016;9588:1295–1305. doi:10.1007/s00277-016-2722-y
   Google Scholar
• Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Bone Marrow Transplant. 1997;20:21–26. doi:10.1038/sj.bmt.1700838
   PubMed Web of Science ®Google Scholar
• Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, et al. Outcomes and prognostic factors in advanced Hodgkin’s disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol. 2004;15(8):1222–1230. doi:10.1093/annonc/mdh304
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-9
   PubMed Web of Science ®Google Scholar
• Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(12):1343–1349. doi:10.1016/j.bbmt.2006.08.039
   PubMed Web of Science ®Google Scholar
• Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. doi:10.1016/0140-6736(93)92411-l
   PubMed Web of Science ®Google Scholar
• Daw S, Hasenclever D, Mascarin M, et al. Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. HemaSphere. 2020;4(1):e329. doi:10.1097/HS9.0000000000000329
   PubMed Web of Science ®Google Scholar
• Williams CD, Goldstone AH, Pearce R, et al. Autologous bone marrow transplantation for pediatric Hodgkin’s disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol. 1993;11(11):2243–2249. doi:10.1200/JCO.1993.11.11.2243
   PubMed Web of Science ®Google Scholar
• Baker KS, Gordon BG, Gross TG, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin disease in children and adolescents. J Clin Oncol. 1999;17:825–831. doi:10.1200/JCO.1999.17.3.825
   PubMed Web of Science ®Google Scholar
• Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG; United Kingdom Children’s Cancer Study Group. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol. 2004;26:740–745. doi:10.1097/00043426-200411000-00010
   PubMed Web of Science ®Google Scholar
• Frankovich J, Donaldson SS, Lee Y, Wong RM, Amylon M, Verneris MR. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant. 2001;7:49–57. doi:10.1053/bbmt.2001.v7.pm11215699
   PubMed Web of Science ®Google Scholar
• Verdeguer A, Pardo N, Madero L, et al. Autologous stem cell transplantation for advanced Hodgkin’s disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant. 2000;25:31–34. doi:10.1038/sj.bmt.1702094
   PubMed Web of Science ®Google Scholar
• Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol. 2004;22:4532–4540. doi:10.1200/JCO.2004.02.121
   PubMed Web of Science ®Google Scholar
• Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;42(Suppl 2):S16–S24. doi:10.1038/bmt.2008.278
   PubMedGoogle Scholar
• Garfin PM, Link MP, Donaldson SS, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma. Biol Blood Bone Marrow Transplant. 2015;21:326–334. doi:10.1016/j.bbmt.2014.10.020
   PubMed Web of Science ®Google Scholar
• Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD Study Group. J Clin Ocol. 2005;23(25):6181–6189. doi:10.1200/JCO.2005.07.930
   PubMed Web of Science ®Google Scholar
• Satwani P, Ahn KW, Carreras J, et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015;50:1416–1423. doi:10.1038/bmt.2015.177
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma. 2018;59(8):1861–1870. doi:10.1080/10428194.2017.1403601
   PubMed Web of Science ®Google Scholar
• Shafer JA, Heslop HE, Brenner MK, et al. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010;51:664–670. doi:10.3109/10428190903580410
   PubMed Web of Science ®Google Scholar
• Sumaili H, Al-Kofide A, Al-Seraihi A, et al. Outcome of pediatric patients with lymphoma following stem cell transplant: a single institution report. Leuk Lymphoma. 2015;56(5):1327–1334. doi:10.3109/10428194.2014.951846
   PubMed Web of Science ®Google Scholar
• Metzger ML, Hudson MM, Krasin MJ, et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer. 2010;116:4376–4384. doi:10.1002/cncr.25225
   PubMed Web of Science ®Google Scholar
• Gorde-Grosjean S, Oberlin O, Leblanc T, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte centre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol. 2012;158:649–656. doi:10.1111/j.1365-2141.2012.09199.x
   PubMed Web of Science ®Google Scholar
• Shankar A, Hayward J, Kirkwood A, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165:534–544. doi:10.1111/bjh.12768
   PubMed Web of Science ®Google Scholar
• Belgaumi A, Al-Kofide AA, Jamil-Malik R, Joseph N, Khafaga Y, Sabbah R. Outcome of second line therapy for pediatric patients with Hodgkin lymphoma who relapse following ABVD based therapy. Blood. 2009;114(22):Abstract 2691 (ASH Annual Meeting). doi:10.1182/blood.V114.22.2691.2691
   Google Scholar
• Talleur AC, Flerlage JE, Shook DR, et al. Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience. Bone Marrow Transplant. 2020;55(7):1357–1366. doi:10.1038/s41409-020-0879-4
   PubMed Web of Science ®Google Scholar
• Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicenter, open-label, phase ½ study. Lancet Haematol. 2018;5(10):e450–e461. doi:10.1016/S2352-3026(18)30153-4
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Mooij H, Zijlstra J, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC transplant brave study. Haematologica. 2019;104(4):e151–e153. doi:10.3324/haematol.2018.196899
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2015;385(9980):1853–1862. doi:10.1016/S0140-6736(15)60165-9
   PubMed Web of Science ®Google Scholar